Literature DB >> 19172557

Atypical carcinoid of the larynx and potential complications of the carcinoid syndrome: a case report.

Meena Seshamani1, Eugene Einhorn, Natasha Mirza.   

Abstract

A 47-year-old man with a history of allergic rhinitis presented with a several-month history of nasal symptoms and gastroesophageal reflux disease. He also had clinical depression, for which he had been taking a selective serotonin reuptake inhibitor (SSRI). During evaluation, flexible laryngoscopy incidentally detected a left interarytenoid polyp. Biopsy identified the lesion as a moderately differentiated neuroendocrine carcinoma. In addition to conducting a metastatic workup, we determined that it was necessary to evaluate the functional status of the tumor prior to excision because the SSRI could precipitate a carcinoid syndrome. We discuss the characteristics and management of different neuroendocrine carcinomas of the larynx, and we review the potential complications of the carcinoid syndrome.

Entities:  

Mesh:

Year:  2009        PMID: 19172557

Source DB:  PubMed          Journal:  Ear Nose Throat J        ISSN: 0145-5613            Impact factor:   1.697


  3 in total

1.  Must antidepressants be avoided in patients with neuroendocrine tumors? Results of a systematic review.

Authors:  Elie Isenberg-Grzeda; Meredith MacGregor; Konstantina Matsoukas; Ngai Chow; Diane Reidy-Lagunes; Yesne Alici
Journal:  Palliat Support Care       Date:  2020-10

2.  Paroxetine may cause increase in carcinoebmryonic antigen (CEA).

Authors:  Mehmet Emin Ceylan; Ahmet Turkcan; Urun Ozer
Journal:  Eur J Clin Pharmacol       Date:  2009-12       Impact factor: 2.953

Review 3.  Cutaneous and Subcutaneous Metastases From Atypical Laryngeal Carcinoids: Case Report and Review of the Literature.

Authors:  Kui-Rong Wang; Yuan-Jing Jia; Shui-Hong Zhou; Qin-Ying Wang; Yang-Yang Bao; Zhi-Ying Feng; Hong-Tian Yao; Jun Fan
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.